Welcome to Cancer Research UK

1
Welcome to Cancer Research UK
2
Developing new medicines to beat cancerKate
Miller
3
Overview

• Cancer Research UK
• My background
• What is Drug Development ?
• Our IT challenges

4
Why Work in Cancer Research?

• More than 10 million people per year develop
  cancer worldwide. This is estimated to rise to
  15 million by 2020 (WHO figures).
• 289,000 new cases of cancer are diagnosed every
  year in the UK.
• Someone in the UK is diagnosed with cancer every
  2 minutes.
• More than 1 in 3 of people will develop cancer.
• Cancer is the British publics number 1 fear.

5
Cancer Research UK - Overview

• Worlds largest independent organisation
  dedicated to cancer research
• 4,500 scientists, doctors nurses in more than
  30 cities towns across the UK
• Largest single funder of cancer research in UK
  spending 333 million on research
• Over 46,600 volunteers who give around 6.9
  million hours of their time
• Our research falls into 4 main areas
  Understanding cancer, Treating cancer, Preventing
  cancer, Improving the quality of life for people
  with cancer
• European leader in development of anti-cancer
  drugs

6
Who am I ?
7
CR-UK 2020 goal

• There will be better treatments with fewer side
  effects.

8
CR-UK Drug development team

• What do we do?
• We provide academic and industrial groups with a
  mechanism for developing their novel oncology
  agents.
• We give patients with terminal cancer hope when
  no other treatment opportunities are available to
  them
• How do we do it?
• We take promising new medicines from the
  laboratory into clinical trials

9
The drug development process
Early-stage research discovery
Regulatory review/ approval
Preclinical studies
Phase I
Phase II
Phase III
Phase IV
2-3 years
1-2 years
? years
1-2 years
1-2 years
1-2 years
CTAAC
Drug Development Office
CRT
10
Our project portfolio - source of new agents ?
11
What happens to the drugs after our studies..?

• DDO undertakes further studies
• and/or
• Company undertakes further studies, or
• It is dropped - too toxic, does not do what it is
  supposed to
• To be successful .. it must be taken on by a
  biotech or pharmaceutical company

12
Drug Development Team successes

• We have advanced gt100 novel agents into early
  phase clinical trials
• 5 of these have reached the market and another 6
  are currently in Phase III development

13
Temozolomide - a success story

• Temozolomide was discovered in a CR-UK research
  laboratory.
• The DDO conducted Phase I II studies
• CRT licensed the drug to Schering Plough
• Schering-Plough conducted Phase III study and got
  the drug approved by regulatory authorities
• Temozolomide sales have now reached 1bn and the
  royalties we receive go straight back into the
  pot to fund further research

14
Drug Development Team - successes

• We have a patient who has moved from progressive
  to stable disease and has successfully completed
  I year of treatment.

15
Drug Development

• What are our main IT Challenges ?

16
Our IT strategy

• To Re-engineer DDO processes and IT
  infrastructure in order to support our strategic
  objective to double drug development activity
  over the next 5 years.
• Where we are today
• As-Is Project. Created an interactive map of all
  our current processes / systems / technologies.
• Thorough understanding of our strengths and
  weaknesses

17
Next Steps

• Quick Win Projects to shore up our current ways
  of working
• Investigate buying new technology
• Investigate renting new technologies
• Investigate outsourcing models
• Trial different models
• Decision

18
Operating in an increasingly regulated
environment
19
Impact of current financial climate

• Looking at investment in infrastructure during a
  difficult financial climate
• Explaining to the general public that investing
  in IT is key to improving drug development
• Ensuring that we spend the publics money wisely

20

• Thank you